Setting Your Rx Coordinates: Navigating the Evolving Rx Landscape in 2024

The ProCare Rx Team • March 7, 2024

With the new year comes new Rx updates to plan for and keep an eye on.

At ProCare Rx, we’ve got our eyes constantly on the horizon, watching for any movement in the industry that could affect you. Two specific areas include specialty drugs and biosimilars. Research shows that prescription costs are projected to rise nearly 10% this year alone. Specialty drugs, on the other hand, are predicted to rise by 15%, growing at a faster and more concerning rate. 1  With the similarly growing demand for specialty drugs, it’s a good time for employers to start planning for how they will cover these medications.


Here are a few things to keep in mind about the drug landscape and specialty Rx costs.


GLP-1s and Weight Loss Drugs

While not necessarily considered a traditional specialty drug, weight loss medications like GLP-1s (Glucagon-like Peptide-1) are growing in popularity—and cost—enough that employers will need to take them into account. GLP-1s in particular are necessary for treating diabetes, supporting blood sugar regulation, helping with weight loss, and reducing cardiovascular risk, making it even more important to account for in 2024. 2


Recent surveys show that interest in the drug could cause GLP-1 coverage to nearly double in the upcoming years – with weight-loss drugs possibly adding up to 50% to healthcare spend. 1


Tracking patient use, planning for pharmacy and medical benefits to work together, and determining how a plan will help cover the drugs, are pharmacy benefit strategies that can assist plan sponsors in managing their impact on pharmacy spend.


Biosimilars

In 2023, lower-cost alternatives to biologic drugs, biosimilars, took the stage. Multiple biosimilars were approved, one of which was the alternative to Humira, a costly blockbuster drug. The adoption of biosimilars presents an opportunity for extensive cost savings—but this adoption is proceeding slower than expected, with research showing that only 2.4% of Humira biologic claims were replaced by biosimilars. 2  Keeping on top of the changes in the Rx landscape from biosimilars is vital. Transparency with PBMs is particularly critical in order to develop effective strategies and plan for the future.


New Legislation

The pharmacy landscape underwent legislative shifts in 2023 that look to continue in 2024. With national attention from the White House and continuing legislation around PBM transparency, it’s important to watch for the impact new laws and regulations can have on pharmacy. With the announcement of the first ten products subject to negotiation under the Inflation Reduction Act (IRA), 3 it’s absolutely necessary to stay proactive in managing new drugs like biosimilars and GLP-1s, and to remain aware of these rapidly changing external dynamics.


At ProCare Rx, we’re dedicated to putting you first.  With claim-level transparent healthcare solutions and the highest level of customer service—we can deliver the best pharmacy claims platform in the industry.  As a direct-source PBM, we will equip you with whatever you need to face new industry updates and regulations with full confidence.  We’ve got your back.


Interested in learning how we can help you? Talk to an Expert!


Sources:

  1. https://www.benefitspro.com/2023/12/26/3-thing-to-know-about-specialty-pharmacy-in-2024/
  2. https://truveris.com/2024-pharmacy-outlook-top-5-pharmacy-benefits-trends/#:~:text=As%20we%20enter%202024%2C%20several,dynamics%20in%20pharmacy%20is%20critical.
  3. https://www.zs.com/insights/trends-shaping-pharmaceutical-landscape-2024-and-beyond

About ProCare Rx
ProCare Rx is a privately held, independent pharmacy benefit manager (PBM) that has empowered healthcare and self-insured organizations since 1988. We provide fully integrated, in-house solutions—including claims adjudication, clinical program design, pharmacy network access, cost containment, and data analytics—all supported in the U.S. Our flexible, transparent model serves self-insured employers, third-party administrators (TPA), brokers, health plans, health systems, managed care organizations (MCO), unions, workers’ compensation programs, Medicare, Medicaid, hospices, and other PBMs. With a proprietary technology platform, commitment to ethical operations, and a focus on lowest net cost, ProCare Rx delivers long-term value, clinical performance, and trusted pharmacy benefit partnerships.

Media Contact:
Marc Cohen, VP, Marketing and Sales
marketing@ProCareRx.com

By ProCare Rx Team October 1, 2025
Drug costs continue to surge, regulatory winds are shifting, and employers are bracing for steeper expenses ahead. Now more than ever, your choice of PBM partner can be a major differentiator or a liability. Why This Moment Matters Cost growth expectations are steep. Employers are forecasting higher health care costs in 2026, with pharmacy spend as a central contributor. Some projections suggest pharmacy alone may rise by double digits next year, far outpacing general medical cost trends. Reform pressure is building. PBM practices are under increasing scrutiny. Policymakers, physician groups, and pharmacy organizations are pushing for reforms that would delink PBM profits from drug list prices, increase transparency, and ensure savings flow to plan sponsors and patients. PBMs themselves are already floating proposals to adjust their practices ahead of possible legislation. Regulation is becoming inconsistent and complex. While federal courts and Congress weigh in, states continue to pass new PBM laws. For multi-state employers, this means navigating a patchwork of rules that can be confusing, sometimes conflicting, and potentially at odds with fiduciary obligations. What to Look for in a PBM Partner Given this evolving landscape, employers should place extra emphasis on: Regulatory agility and compliance support Your PBM must help you navigate both federal and state-level requirements, protecting your plan against compliance risk. True cost transparency and incentive alignment Demand clarity on how your PBM is compensated. Incentives should be aligned with your plan, not tied to higher drug list prices or opaque rebate arrangements. Formulary integrity and clinical governance With expensive therapies hitting the market, your PBM should balance cost savings with clinical appropriateness, ensuring members receive the right drug, not just the cheapest option. Benefit design flexibility Rising costs require innovative plan designs such as specialty carve-outs, differential cost-sharing, or utilization management. Your PBM should be a partner in shaping these strategies, not a barrier. Member experience and adoption tools With members facing higher cost-sharing and more complex therapies, digital tools, adherence programs, and proactive engagement are essential for better outcomes. Proven performance and benchmarking In this climate, results matter. Your PBM should demonstrate measurable cost savings and clinical outcomes year over year, benchmarked against peers. The Bottom Line  Plan sponsors are entering a pivotal moment. The forces shaping pharmacy benefits include cost escalation, regulatory change, and clinical complexity. The status quo will not be enough. Choosing a PBM partner with regulatory foresight, aligned incentives, clinical integrity, and member-centric tools can help employers navigate this era, mitigate risk, and deliver sustainable value to their workforce. Sources Reuters – Pharma middlemen propose regulatory changes to avoid Trump administration rules Pharmacy Times – Pharmacy policy updates for September 2025 Bloomberg Law – Drug benefit compliance is a state-by-state test for sponsors NASPA – Over 100 pharmacy organizations urge PBM reform AMA – Advocacy update spotlight on PBMs Healthcare Dive – Employers expect 9% higher health costs in 2026 WorldatWork – Business Group on Health predicts 9% higher healthcare costs in 2026 PwC – Behind the numbers: Rising drug spend ProCare Rx PBM 101 video script
By ProCare Rx September 29, 2025
The world of pharma is evolving quickly, with direct-to-consumer (DTC) marketing and new patient engagement strategies changing how therapies are launched, prescribed, and accessed. Join John Drakulich for an insightful conversation on The New Pharma Playbook and what these shifts mean for employers, health plans, pharmacies, and patients. Hosted by ProCare Rx , this webinar takes a closer look at how DTC marketing influences prescribing behavior, patient decision-making, and overall drug costs, and how transparent PBM strategies can help plan sponsors navigate these challenges while prioritizing member care. Attendees will walk away with practical insights into how PBMs like ProCare Rx are driving innovation, improving access, and keeping costs under control in a changing marketplace.
By ProCare Rx Team September 5, 2025
PBM 101, Part 1: Why PBMs Matter for Employers
By ProCare Rx Team August 28, 2025
ProCare Rx appoints Marco Torelli as new SVP of Labor and Public Sector
By ProCare Rx Team August 27, 2025
ProCare Rx Names JD Edwards Senior Vice President of Sales
By ProCare Rx Team August 18, 2025
This appointment brings together multiple parts of the business under one umbrella to best serve our PBM clients and members, assuring that ClearSight transparency and Lowest Net Cost remains at the forefront of the innovative organization.
By ProCare Rx Team August 5, 2025
When Courts and Care Collide: What the Arkansas PBM Ruling Means for the Industry
By ProCare Rx Team July 8, 2025
Prescription Drug Pricing: Will Policy Fix What Patients Feel?
By ProCare Rx Team June 2, 2025
Is Your PBM Working for You…Or Against You? How to Ask the Right Questions and Spot Red Flags in Pharmacy Benefit Management
By ProCare Rx May 20, 2025
ProCare Rx Announces New Executive Appointment and Launch of Technology Division to Drive Innovation and Growth The newly created role is expected to solidify leadership of the core technology infrastructure to both enhance support for current clients as well as developing additional value-added offerings to the marketplace.